These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 14872430

  • 1. Safety profile of recombinant factor VIIa.
    Roberts HR, Monroe DM, Hoffman M.
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):101-8. PubMed ID: 14872430
    [Abstract] [Full Text] [Related]

  • 2. Recombinant factor VIIa (Novoseven) and the safety of treatment.
    Roberts HR.
    Semin Hematol; 2001 Oct; 38(4 Suppl 12):48-50. PubMed ID: 11735111
    [Abstract] [Full Text] [Related]

  • 3. Dosing with recombinant factor viia based on current evidence.
    Hedner U.
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):35-9. PubMed ID: 14872419
    [Abstract] [Full Text] [Related]

  • 4. Recombinant factor VIIa in patients with coagulopathy secondary to anticoagulant therapy, cirrhosis, or severe traumatic injury: review of safety profile.
    Levy JH, Fingerhut A, Brott T, Langbakke IH, Erhardtsen E, Porte RJ.
    Transfusion; 2006 Jun; 46(6):919-33. PubMed ID: 16734808
    [Abstract] [Full Text] [Related]

  • 5. Safety analysis of rFVIIa with emicizumab dosing in congenital hemophilia A with inhibitors: Experience from the HAVEN clinical program.
    Levy GG, Asikanius E, Kuebler P, Benchikh El Fegoun S, Esbjerg S, Seremetis S.
    J Thromb Haemost; 2019 Sep; 17(9):1470-1477. PubMed ID: 31124272
    [Abstract] [Full Text] [Related]

  • 6. Update on Novo Nordisk's clinical trial programme on NovoSeven.
    Dejgaard A.
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S39-41. PubMed ID: 14567535
    [Abstract] [Full Text] [Related]

  • 7. Recombinant-activated coagulation factor VIIa (NovoSeven): current development.
    Weiskopf RB.
    Vox Sang; 2007 May; 92(4):281-8. PubMed ID: 17456151
    [Abstract] [Full Text] [Related]

  • 8. Recombinant activated factor VIIa and hemostasis in critical care: a focus on trauma.
    Mohr AM, Holcomb JB, Dutton RP, Duranteau J.
    Crit Care; 2005 May; 9 Suppl 5(Suppl 5):S37-42. PubMed ID: 16221318
    [Abstract] [Full Text] [Related]

  • 9. Potential role of recombinant factor VIIa as a hemostatic agent.
    Hedner U, Erhardtsen E.
    Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
    [Abstract] [Full Text] [Related]

  • 10. Tissue factor-independent effects of recombinant factor VIIa on hemostasis.
    Weeterings C, Lisman T, de Groot PG.
    Semin Hematol; 2008 Apr; 45(2 Suppl 1):S12-5. PubMed ID: 18544417
    [Abstract] [Full Text] [Related]

  • 11. Clinical experience with activated factor VII: focus on safety aspects.
    Roberts HR.
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S115-8. PubMed ID: 9819041
    [Abstract] [Full Text] [Related]

  • 12. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors.
    Abshire T, Kenet G.
    J Thromb Haemost; 2004 Jun; 2(6):899-909. PubMed ID: 15140125
    [Abstract] [Full Text] [Related]

  • 13. Recombinant factor VIIa (rFVIIa) and its use in severe bleeding in surgery and trauma: a review.
    Grounds M.
    Blood Rev; 2003 Sep; 17 Suppl 1():S11-21. PubMed ID: 14697209
    [Abstract] [Full Text] [Related]

  • 14. Analysis and results of the recombinant factor VIIa extended-use registry.
    Laffan M, O'Connell NM, Perry DJ, Hodgson AJ, O'Shaughnessy D, Smith OP.
    Blood Coagul Fibrinolysis; 2003 Jun; 14 Suppl 1():S35-8. PubMed ID: 14567534
    [Abstract] [Full Text] [Related]

  • 15. Mechanism of action of recombinant activated factor VII: an update.
    Hedner U.
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S105-7. PubMed ID: 16427375
    [Abstract] [Full Text] [Related]

  • 16. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
    Scharrer I.
    Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
    [Abstract] [Full Text] [Related]

  • 17. Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency.
    Brenner B, Wiis J.
    Hematology; 2007 Feb; 12(1):55-62. PubMed ID: 17364994
    [Abstract] [Full Text] [Related]

  • 18. A novel hemostatic agent: the potential role of recombinant activated factor VII (rFVIIa) in anesthetic practice.
    Murkin JM.
    Can J Anaesth; 2002 Dec; 49(10):S21-6. PubMed ID: 12546007
    [Abstract] [Full Text] [Related]

  • 19. Effect of the administration of recombinant activated factor VII (rFVIIa; NovoSeven) in the management of severe uncontrolled bleeding in patients undergoing heart valve replacement surgery.
    Al Douri M, Shafi T, Al Khudairi D, Al Bokhari E, Black L, Akinwale N, Osman Musa M, Al Homaidhi A, Al Fagih M, Borum Andreasen R.
    Blood Coagul Fibrinolysis; 2000 Apr; 11 Suppl 1():S121-7. PubMed ID: 10850577
    [Abstract] [Full Text] [Related]

  • 20. Recombinant activated factor VII (NovoSeven): addition to replacement therapy in acute, uncontrolled and life-threatening bleeding.
    Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O.
    Vox Sang; 2004 Jul; 87(1):34-40. PubMed ID: 15260820
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.